| 國立成功大學 |
2023 |
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
|
Peng, K.;Blais, J.E.;Pratt, N.L.;Guo, J.J.;Hillen, J.B.;Stanford, T.;Ward, M.;Lai, E.C.-C.;Shin, J.-Y.;Tong, X.;Fan, M.;Cheng, F.W.T.;Wu, J.;Yeung, W.W.Y.;Lau, C.-S.;Leung, W.K.;Wong, I.C.K.;Li, X. |
| 臺大學術典藏 |
2022-09-06T07:43:35Z |
Screening for gastric cancer in Asia: current evidence and practice
|
Leung W.K.; MING-SHIANG WU; Kakugawa Y.; Kim J.J.; Yeoh K.-g.; Goh K.L.; Wu K.-c.; Wu D.-c.; Sollano J.; Kachintorn U.; Gotoda T.; Lin J.-t.; You W.-c.; Ng E.K.; Sung J.J. |
| 國立成功大學 |
2022 |
Monoclonal antibodies and Fc-fusion protein biologic medicines: A multinational cross-sectional investigation of accessibility and affordability in Asia Pacific regions between 2010 and 2020
|
Tong, X.;Li, X.;Pratt, N.L.;Hillen, J.B.;Stanford, T.;Ward, M.;Roughead, E.E.;Lai, E.C.-C.;Shin, J.-Y.;Cheng, F.W.T.;Peng, K.;Lau, C.S.;Leung, W.K.;Wong, I.C.K. |
| 臺大學術典藏 |
2021-06-15T03:12:16Z |
The Asia-Pacific consensus on ulcerative colitis
|
Ooi C.J.; Fock K.M.; Makharia G.K.; Goh K.L.; Ling K.L.; Hilmi I.; Lim W.C.; Kelvin T.; Gibson P.R.; Gearry R.B.; Ouyang Q.; Sollano J.; Manatsathit S.; Rerknimitr R.; SHU-CHEN WEI; Leung W.K.; De Silva H.J.; Leong R.W. |
| 臺大學術典藏 |
2021-06-15T03:12:04Z |
Asia Pacific Consensus Statements on Crohn's disease. Part 1: Definition, diagnosis, and epidemiology: (Asia Pacific Crohn's Disease Consensus-Part 1)
|
Ooi C.J.; Makharia G.K.; Hilmi I.; Gibson P.R.; Fock K.M.; Ahuja V.; Ling K.L.; Lim W.C.; Thia K.T.; SHU-CHEN WEI; Leung W.K.; Koh P.K.; Gearry R.B.; Goh K.L.; Ouyang Q.; Sollano J.; Manatsathit S.; de Silva H.J.; Rerknimitr R.; Pisespongsa P.; Abu Hassan M.R.; Sung J.; Hibi T.; Boey C.C.M.; Moran N.; Leong R.W.L.; on behalf of the Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease |
| 臺大學術典藏 |
2021-06-15T03:12:04Z |
Asia-Pacific consensus statements on Crohn's disease. Part 2: Management
|
Ooi C.J.; Makharia G.K.; Hilmi I.; Gibson P.R.; Fock K.M.; Ahuja V.; Ling K.L.; Lim W.C.; Thia K.T.; SHU-CHEN WEI; Leung W.K.; Koh P.K.; Gearry R.B.; Goh K.L.; Ouyang Q.; Sollano J.; Manatsathit S.; de Silva H.J.; Rerknimitr R.; Pisespongsa P.; Abu Hassan M.R.; Sung J.; Hibi T.; Boey C.C.M.; Moran N.; Leong R.W.L.; on behalf of the Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease |
| 臺大學術典藏 |
2021-06-15T03:11:54Z |
Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia
|
Ooi C.J.; Hilmi I.; Banerjee R.; Chuah S.W.; Ng S.C.; SHU-CHEN WEI; Makharia G.K.; Pisespongsa P.; Chen M.H.; Ran Z.H.; Ye B.D.; Park D.I.; Ling K.L.; Ong D.; Ahuja V.; Goh K.L.; Sollano J.; Lim W.C.; Leung W.K.; Ali R.A.R.; Wu D.C.; Ong E.; Mustaffa N.; Limsrivilai J.; Hisamatsu T.; Yang S.K.; Ouyang Q.; Geary R.; De Silva J.H.; Rerknimitr R.; Simadibrata M.; Abdullah M.; Leong R.W.L.; on behalf of the Asia-Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease; Asian Organization for Crohn's; Colitis |
| 臺大學術典藏 |
2021-06-15T03:11:54Z |
Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia
|
Ooi C.J.; Hilmi I.; Banerjee R.; Chuah S.W.; Ng S.C.; SHU-CHEN WEI; Makharia G.K.; Pisespongsa P.; Chen M.H.; Ran Z.H.; Ye B.D.; Park D.I.; Ling K.L.; Ong D.; Ahuja V.; Goh K.L.; Sollano J.; Lim W.C.; Leung W.K.; Ali R.A.R.; Wu D.C.; Ong E.; Mustaffa N.; Limsrivilai J.; Hisamatsu T.; Yang S.K.; Ouyang Q.; Geary R.; De Silva J.H.; Rerknimitr R.; Simadibrata M.; Abdullah M.; Leong R.W. |
| 臺大學術典藏 |
2021-06-15T03:11:52Z |
Stopping anti-tumour necrosis factor therapy in patients with perianal Crohn’s disease
|
Mak J.W.Y.; Tang W.; Yip T.C.F.; Ran Z.H.; SHU-CHEN WEI; Ahuja V.; Kumar S.; Leung W.K.; Hilmi I.; Limsrivilai J.; Aniwan S.; Lam B.C.Y.; Chan K.H.; Ng K.M.; Leung C.M.; Li M.K.K.; Lo F.H.; Sze A.S.F.; Tsang S.W.C.; Hui A.J.; Hartono J.L.; Ng S.C. |
| 臺大學術典藏 |
2021-06-15T03:11:51Z |
Asian Pacific Association of Gastroenterology (APAGE) Inflammatory Bowel Disease (IBD) Working Party guidelines on IBD management during the COVID-19 pandemic
|
Ling K.L.; Hilmi I.; Raja Ali R.A.; Leong R.W.L.; Leung W.K.; Ng S.C.; Wu K.C.; Chen M.H.; Ran Z.H.; Hisamatsu T.; Ahuja V.; Makharia G.K.; Banerjee R.; SHU-CHEN WEI; Wu D.C.; Pisespongsa P.; Ye B.D.; Sollano J.; Simadibrata M.; Chuah S.W.; Ooi C.J. |
